Heart Failure: Diagnosis, Screening, and Treatment
Diagnostic Evaluation
Transthoracic echocardiography (TTE) is the essential first-line imaging test for any patient with suspected heart failure to assess myocardial structure, function, and determine left ventricular ejection fraction (LVEF), which dictates the entire treatment pathway 1.
Initial Diagnostic Workup
When evaluating suspected heart failure, proceed algorithmically:
Step 1: Clinical Assessment
- Look specifically for multiple signs of hypervolemia: jugular venous distension, peripheral edema (bilateral lower extremity), pulmonary rales, hepatojugular reflux, and S3 gallop 2
- Assess for exertional dyspnea, particularly in older adults with obesity, atrial fibrillation, hypertension, or diabetes 3
- Note that obesity significantly limits physical exam accuracy and may require alternative diagnostic approaches 2
Step 2: Natriuretic Peptide Testing
- Measure B-type natriuretic peptide (BNP) or NT-proBNP levels 2, 4
- Use NT-proBNP ≥125 pg/mL as the screening threshold 5
- Critical caveat: Natriuretic peptides may be falsely low in obese patients, limiting diagnostic accuracy 2, 3
Step 3: Echocardiography
- TTE is mandatory to establish diagnosis and classify heart failure type (HFrEF, HFmrEF, or HFpEF) 1
- LVEF determination is essential for selecting evidence-based pharmacological and device therapies 1
- In patients with intermediate probability after initial testing, proceed to exercise stress echocardiography 3
- For persistent diagnostic uncertainty despite negative noninvasive testing, invasive hemodynamic exercise testing may be necessary 3
Diagnostic Scoring Systems
For primary care screening in high-risk populations:
- HFpEF-ABA and BREATH2 scores help estimate pre-test probability and guide referral decisions 3
- In specialty settings, H2FPEF and HFA-PEFF scores (incorporating natriuretic peptides and comprehensive echocardiography) are useful to rule in HFpEF 3
- These scores have limited sensitivity to rule out HFpEF, especially in obesity 3
Screening Recommendations
Screen asymptomatic patients with hypertension and/or diabetes using a stepwise strategy: symptom assessment first, followed by NT-proBNP or hand-held echocardiography based on initial findings 5. This approach achieves 100% accuracy with 31.3% cost reduction compared to universal testing 5.
Who to Screen
- Patients with hypertension (to prevent or delay HF onset) 1
- Patients with diabetes and chronic kidney disease 6
- Asymptomatic patients with prior myocardial infarction and LV systolic dysfunction 1
- High-risk populations: older adults with obesity, atrial fibrillation, or multiple cardiovascular risk factors 3
The lifetime risk of heart failure is now 20-30% in developed countries, making screening increasingly important 7.
Treatment Strategies
Prevention in Asymptomatic Patients (Stage A/B)
For patients with asymptomatic LV systolic dysfunction and prior MI, initiate both ACE inhibitor AND beta-blocker to prevent or delay symptomatic heart failure and prolong life 1.
- Hypertension treatment is mandatory to prevent HF onset (Class I, Level A) 1
- ACE inhibitor in asymptomatic LV dysfunction post-MI (Class I, Level A) 1
- Beta-blocker in asymptomatic LV dysfunction post-MI (Class I, Level B) 1
- SGLT2 inhibitors and finerenone are now recommended for HF prevention in diabetic CKD patients 6
Treatment of Symptomatic HFrEF (LVEF ≤35-40%)
The foundation is quadruple therapy: ACE inhibitor (or ARNI), beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor, with rapid up-titration using a "high-intensity care" strategy 1, 6.
Core Quadruple Therapy Algorithm:
ACE Inhibitor + Beta-blocker (both Class I, Level A)
- Start both simultaneously in stable patients
- These form the absolute foundation of HFrEF therapy 1
Add MRA (Class I, Level A)
- For patients remaining symptomatic despite ACE-I and beta-blocker
- Reduces HF hospitalization and death 1
- Monitor potassium and renal function closely
Add SGLT2 Inhibitor (now recommended across entire EF spectrum)
- Major advancement: SGLT2 inhibitors now have Class I recommendation for HFrEF, HFmrEF, and HFpEF 6
Upgrade ACE-I to Sacubitril/Valsartan (ARNI) (Class I, Level B)
- Replace ACE-I (not add to it) in ambulatory patients with persistent symptoms despite optimal therapy
- Further reduces HF hospitalization and death 1
Consider Vericiguat as Fifth Drug
- For patients experiencing worsening HF despite quadruple therapy 6
Rapid Up-Titration Strategy:
The STRONG-HF trial demonstrated that early, rapid up-titration with close follow-up (high-intensity care) after acute HF improves outcomes 6. This means:
- Frequent clinical reassessment
- Aggressive laboratory monitoring
- Quick dose escalation rather than prolonged conservative titration
Symptomatic Management:
- Diuretics (Class I, Level B): Essential for congestion relief and symptom improvement 1
- Consider natriuresis-guided diuretic therapy per PUSH-AHF data 6
Device Therapy for HFrEF
Primary Prevention ICD:
- Indicated for symptomatic HF (NYHA II-III), LVEF ≤35% despite ≥3 months optimal medical therapy, expected survival >1 year with good functional status (Class I, Level A for ischemic cardiomyopathy; Class I, Level B for dilated cardiomyopathy) 1
- NOT within 40 days of MI (Class III, Level A) - implantation at this time does not improve prognosis 1
Secondary Prevention ICD:
- For patients recovered from hemodynamically unstable ventricular arrhythmia (Class I, Level A) 1
Cardiac Resynchronization Therapy (CRT):
- Recommended for symptomatic HF patients in sinus rhythm with QRS ≥150 msec, LBBB morphology, and LVEF ≤35% 1
Treatment of HFpEF
SGLT2 inhibitors are now the cornerstone pharmacotherapy for HFpEF across the entire ejection fraction spectrum 6.
Additional HFpEF-specific therapies:
- Semaglutide 2.4 mg weekly for obese HFpEF patients: STEP-HFpEF trials showed decreased body weight, improved quality of life, and increased 6-minute walk distance over 1 year 6
- Further data on hard endpoints (mortality, hospitalization) are needed before definitive recommendation
Specific Cardiomyopathy Treatments
- Mavacamten for hypertrophic cardiomyopathy 6
- Tafamidis for transthyretin cardiac amyloidosis 6
- Early diagnosis of amyloidosis is increasingly emphasized in recent guidelines 7
Iron Deficiency Treatment
Address iron deficiency in HF patients, as this is now a recognized treatment target 7.
Critical Contraindications
Never use diltiazem or verapamil in HFrEF (Class III, Level C) - they increase HF worsening and hospitalization risk 1.
Do not combine ARB (or renin inhibitor) with both ACE-I AND MRA (Class III, Level C) - this triple combination increases renal dysfunction and hyperkalemia risk 1. You can use ACE-I + MRA, or ARB + MRA, but not all three renin-angiotensin-aldosterone system inhibitors simultaneously.
Implementation Pitfalls
Obesity challenges: Physical exam, imaging quality, and NT-proBNP accuracy are all compromised. Consider risk scores, empiric diuretic trials, or invasive testing when diagnosis remains uncertain 2.
Post-MI timing: Wait 40 days after MI before ICD implantation for primary prevention 1.
Underutilization of quadruple therapy: Many patients remain on incomplete regimens. The evidence strongly supports rapid implementation of all four medication classes in HFrEF 6.
HFpEF underdiagnosis: Many patients are managed for comorbidities without recognizing underlying HFpEF. Maintain high clinical suspicion in older adults with exertional dyspnea and risk factors 3.
Delayed specialist referral: Primary care should use validated scores (HFpEF-ABA, BREATH2) to identify patients needing cardiology evaluation 3.